Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308997 · ClinicalTrials.gov registry record · Phase 2
Transcranial Magnetic Stimulation for "Voices"
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00308997: Completed Phase 2 study, sponsored by Yale University.
NCT00308997 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308997, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder. In addition, the study will determine duration of improvement obtained during the course of trial participation via on-going monthly contact with study participants for up to 1 year after the trial.
Primary Outcome
HCS score for participants assessed after 5 sessions, 16 minutes per session, who received either rTMS or sham stimulation delivered to the right superior temporal gyrus. HCS was anchored at 0 (corresponding to no AVHs), 10 (no change in hallucination severity) and 20 (AVHs twice as severe as baseline). Lower scores correspond to greater improvement
Interventions
- DEVICE 1-hertz Repetitive Transcranial Magnetic Stimulation
- DEVICE Active 1-Hertz Repetitive transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT00308997 record still lists
NCT00308997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which 1-hertz Repetitive Transcranial Magnetic Stimulation is the first listed.
NCT00308997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00308997 about?
NCT00308997 is a clinical study titled "Transcranial Magnetic Stimulation for "Voices"". This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder. In addition, the study will determine duration of improvement obtained during the course of trial...
What is the current status of trial NCT00308997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2006-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00308997?
The interventions under investigation include: 1-hertz Repetitive Transcranial Magnetic Stimulation (DEVICE), Active 1-Hertz Repetitive transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT00308997?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00308997's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia